Alnylam's Liver Cancer RNAi Program Enters The Clinic
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Alnylam Pharmaceuticals's ALN-VSP RNA interference program has begun clinical trials in patients with advanced liver cancers, the Cambridge-MA.-based biotech said April 3
You may also be interested in...
Alnylam Finds Partner For Liver Cancer Program In China’s Ascletis
U.S.-China hybrid Ascletis is in-licensing rights to Phase II-ready RNA-interference program ALN-VSP from Alnylam with an eye on developing a groundbreaking therapy for an underserved indication that hits especially hard in China.
Ascletis Strategy Begins To Reach Fruition In Deal With Alnylam For HCC Candidate
U.S.-China hybrid Ascletis is in-licensing rights to Phase II-ready RNA-interference program ALN-VSP from Alnylam with an eye on developing a groundbreaking therapy for an underserved indication that hits especially hard in China.
Alnylam Set To Bring 3rd Program Into Clinic; Continue Progress Of Other Two
Alnylam plans to file an IND at FDA by the end of this year for a drug candidate to treat transthyretin-mediated amyloidosis (ATTR), with a goal of beginning Phase I study early next year, the biotech reported during an investor research and development presentation Nov. 12 (see chart: "1Alnylam's Aggressive Business Development Program Has Yielded Results")